Skip to main content
TIBET AIM PHARM. INC. logo

TIBET AIM PHARM. INC. — Investor Relations & Filings

Ticker · 002826 ISIN · CNE100002C39 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,085 across all filing types
Latest filing 2022-04-21 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002826

About TIBET AIM PHARM. INC.

https://www.emyy.cn

Tibet Aim Pharm. Inc. is a pharmaceutical enterprise focused on the research, development, production, and distribution of medicinal products. The company integrates traditional Tibetan medicine with modern pharmaceutical manufacturing processes to develop a diverse portfolio of treatments. Its core product range typically includes cardiovascular medications, digestive system therapies, and specialized herbal formulations derived from high-altitude botanical sources. Tibet Aim Pharm. Inc. emphasizes the modernization of traditional formulas through rigorous clinical testing and standardized production techniques. The company serves healthcare providers and patients by providing therapeutic solutions that bridge ancient medical knowledge with contemporary scientific standards.

Recent filings

Filing Released Lang Actions
独立董事对担保等事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on various matters discussed at the company's third board of directors' fifth meeting. It covers topics such as the 2021 fundraising usage report, related party transactions, internal control self-evaluation, profit distribution plan, reappointment of the audit firm, use of own funds for cash management, and stock repurchase plans. The document is a formal opinion letter related to board meeting matters, not a full financial report or audit report itself. It does not contain detailed financial statements or comprehensive financial data but rather expresses independent opinions on specific agenda items. This fits best under Board/Management Information (MANG), which includes announcements of board-related matters and opinions from directors. The document length is 2188 characters, relatively short and focused on board opinions rather than full reports or announcements of report publications.
2022-04-21 Chinese
关于续聘会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of an audit firm (Lixin Certified Public Accountants) for the company's 2022 financial audit services. It details the qualifications, experience, and independence of the audit firm and the audit team, as well as the approval process by the board, audit committee, independent directors, and supervisory board. The document does not contain any actual financial statements or audit reports but is a formal notice about the intention to continue the audit engagement, pending shareholder approval. The document length is 3661 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document fits the category of an Audit Report / Information announcement about the audit firm reappointment rather than the audit report itself. FY 2021
2022-04-21 Chinese
内部控制鉴证报告
Regulatory Filings
2022-04-21 Chinese
2021年年度报告
Annual Report Classification · 100% confidence The document is titled "西藏易明西雅医药科技股份有限公司 2021 年年度报告全文" which translates to "Tibet Aim Pharmaceutical Technology Co., Ltd. 2021 Annual Report Full Text." It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, corporate governance, environmental and social responsibility, and financial statements. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. It includes audited financial data, management analysis, and comprehensive disclosures. Therefore, this document is the official yearly report covering company activity and full financial performance, matching the definition of an Annual Report (10-K). FY 2021
2022-04-21 Chinese
易明医药2021年度业绩快报
Earnings Release Classification · 95% confidence The document is titled as a '2021年度业绩快报' which translates to '2021 Annual Performance Express Report' or 'Earnings Quick Report'. It contains preliminary financial data for the year 2021, including revenue, profit, earnings per share, and other key financial metrics. The document explicitly states that the data is preliminary, internally audited but not yet audited by an external accounting firm, and may differ from the final annual report. The length is 1434 characters, which is quite short and typical for an earnings release or earnings quick report rather than a full annual report. It includes key financial highlights and a brief explanation of performance changes, consistent with an Earnings Release (ER). It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and detailed analysis. It is not an announcement of a report publication (RPA) because it contains actual financial data, not just a notice. Therefore, the best classification is Earnings Release (ER). FY 2021
2022-04-08 Chinese
关于大股东部分股份解除质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the release of a portion of shares pledged by a major shareholder. It details the shareholder's name, number of shares released from pledge, pledge dates, and related information. There is no financial report, earnings data, or management discussion. The document is short (1356 characters) and focuses on share pledge status, which is a capital structure related update. This fits the category of Capital/Financing Update (CAP).
2022-04-05 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.